Navigation Links
First U.S. Patients Enrolled in the REALISM Continued Access Study

MENLO PARK, Calif., Feb. 2 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today the start of enrollment in the REALISM (Real World ExpAnded MuLtIcenter Study of the MitraClip(R) System) study, a continued access registry. The MitraClip(R) system is currently being evaluated in the United States as a non-surgical treatment option for patients suffering from the effects of mitral regurgitation (MR). EVEREST II, the only randomized trial comparing a percutaneous mitral repair device to mitral valve surgery, successfully completed enrollment in 2008.

MR affects millions of people worldwide and is the most common type of heart valve insufficiency in the United States and Europe. The vast majority of patients with significant MR are untreated, which leaves their hearts affected by the chronic volume overload caused by MR, requiring the heart to work harder, and ultimately leading to heart failure.

The first patient was enrolled in REALISM by Peter Fail, M.D., and his team at Terrebonne Regional Medical Center in Houma, Louisiana.

"Based on my experience treating patients with the MitraClip(R) system during EVEREST II, I am eager to participate in the REALISM study," said Dr. Fail, director of the cardiac catheterization lab and principal investigator at Terrebonne Regional Medical Center. "I often see patients who may be candidates for the MitraClip(R) therapy and I am glad they now have an option to participate in the continuation of this landmark trial and potentially benefit from this alternative treatment."

The REALISM study is a prospective, multi-center, continued access registry of the EVEREST II study. The REALISM study consists of two arms: a high risk arm and a non-high risk arm. Up to 300 patients will be enrolled in the study at clinical sites in the United States. Patients will undergo 30- day, 6-month and 12-month clinical follow-up. REALISM will collect new information regarding functional capacity following treatment with the MitraClip(R) device.

"The REALISM study will allow patients suffering from the effects of MR to continue to have access to the MitraClip(R) therapy under a controlled protocol while data from the EVEREST II trial are being finalized," said Ted Feldman, M.D., director of the cardiac catheterization lab at Evanston Hospital and co-principal investigator of the EVEREST trial. "This will also allow us to observe the use of the MitraClip(R) system under real world conditions and will allow us to further study changes in functional capacity after successful treatment with the MitraClip(R) system."

"Initiating enrollment in REALISM is an important milestone for Evalve," said Ferolyn Powell, president and chief executive officer of Evalve. "REALISM allows participating EVEREST investigators continued access to the MitraClip(R) therapy for patients suffering from MR. As we make progress toward filing the MitraClip(R) system premarket approval application with the FDA, this study also allows physicians to gain additional experience with the system and enables patients to potentially benefit from a less invasive treatment option."

The MitraClip(R) system is the only commercially available treatment option for non-surgical mitral valve repair in Europe.

About the MitraClip(R) Procedure

Percutaneous mitral repair with Evalve's MitraClip(R) system is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) therapy may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.

About Evalve, Inc.

Founded in 1999, Evalve, Inc. -headquartered in Menlo Park, California- has developed a proprietary system which enables percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. For more information about Evalve, Inc., and for an animated explanation of the procedure using the MitraClip(R) device, visit Evalve is the first portfolio company from the medical device company incubator, The Foundry (

The MitraClip(R) system is currently undergoing clinical evaluation in the United States and Canada.

MitraClip(R) and Evalve(R) are registered trademarks of Evalve, Inc.

SOURCE Evalve, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
(Date:11/27/2015)... 2015 Ein neuer Kombinationsansatz ...   --> Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint ... Clinical Cancer Research vom 6. ... Research vom 6. November 2015 berichtet. ...
(Date:11/26/2015)... , November 27, 2015 ... --> --> ... emergency response system (PERS) market ... for 5 years with APAC ... expected to see a high ...
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Vasont Systems, ... Vasont Universal Integrator (VUI) extension unites with Syncro Soft’s latest software update, oXygen ... a continuous process with the latest release of oXygen® XML editor and the ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ability to present ... medical schools of the future. To reach an audience of key visionaries and ... conference in Chicago, organized by the American Medical Association. , AMA President ...
(Date:11/30/2015)... ... 30, 2015 , ... Innovaacom, a leading provider of medical ... survey of educational needs for pharmacists worldwide. The poll of pharmacists in Europe, ... quality online and face-to-face education for pharmacists who are fast becoming the new ...
(Date:11/30/2015)... ... November 30, 2015 , ... Several significant coding-related ... changes are likely to include new codes for spine and hip X-rays, paravertebral ... the effects of code changes in musculoskeletal, radiology and nervous system sections on ...
(Date:11/29/2015)... FL (PRWEB) , ... November 30, 2015 , ... ... available today from the new company, Sublime Beauty NATURALS®. All products are available ... natural products, like essential oils, organic facial serums and USDA Certified Organic Sesame ...
Breaking Medicine News(10 mins):